Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
Pelthos Therapeutics Inc. (PTHS)
Company Research
Source: GlobeNewswire
DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has named veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Mr. Einhorn will serve on the Board of Directors until Pelthos’ 2026 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation or removal. Also, effective immediately, Mr. Einhorn will also serve on the Audit Committee and the Compensation Committee of the Pelthos Board of Directors. Mr. Einhorn brings extensive corporate financial management experience to the role, with more than four decades of experience in investment banking and capital markets, as well as in C-level finance roles at fast-paced clinical and commercial-stage life science companies. “Andrew’s extensive capital markets a
Show less
Read more
Impact Snapshot
Event Time:
PTHS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTHS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTHS alerts
High impacting Pelthos Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
PTHS
News
- Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript [Seeking Alpha]Seeking Alpha
- Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%GlobeNewswire
- Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial ResultsGlobeNewswire
PTHS
Earnings
- 11/13/25 - Miss
PTHS
Sec Filings
- 12/23/25 - Form 8-K
- 12/19/25 - Form 4
- 12/17/25 - Form 8-K
- PTHS's page on the SEC website